CTSS and cancer: The potential of cathepsin S as a novel cancer target amenable to antibody mediated therapy has been examined using a murine anti-cathepsin S monoclonal antibody (Fsn0503) which is capable of blocking tumor cell invasion, endothelial tube formation and microvascular sprouting during angiogenesis [23,24].